Global Inflammatory Bowel Disease Market Assessment, By Type [Ulcerative Colitis, Crohn’s Disease], By Drug Class [Corticosteroids, TNF Inhibitors, Aminosalicylates, IL Inhibitors, JAK Inhibitors, Anti-integrin, Others], By Route of Administration [Oral, Injectable], By Distribution [Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others], By Region Opportunities and Forecast, 2017-2031F

Global inflammatory bowel disease market is projected to witness a CAGR of 5.15% during the forecast period 2024-2031, growing from USD 22.07 billion in 2023 to USD 32.98 billion in 2031. 

Inflammatory Bowel Disease Market Size, Share, Growth & Forecast 2031

Global inflammatory bowel disease market is projected to witness a&nbsp;CAGR of 5.15%&nbsp;during the forecast period 2024-2031, growing from&nbsp;USD 22.07 billion&nbsp;in 2023 to&nbsp;USD 32.98 billion&nbsp;in 2031. The market demand for Inflammatory Bowel Disease is anticipated to thrive drastically in the forecast years due to rising prevalence and the growing interest of investors and market players.
Inflammatory Bowel Disease is a chronic inflammatory condition of the gastrointestinal tract. It includes two types: Ulcerative colitis and Crohn&rsquo;s disease. Ulcerative colitis causes swelling and sores in the colon and rectum. Moreover, Crohn's disease affects the small intestine and large intestine, as well as the mouth, esophagus, stomach and anus. Common inflammatory bowel disease symptoms include abdominal pain, diarrhea (sometimes with blood), weight loss, rectal bleeding, fever, anemia, anxiety and depression. The diagnostic process for IBD involves multiple approaches. Clinicians typically start with a detailed medical history and physical examination. Some of the associated procedures include blood tests to evaluate anemia or inflammation, stool tests to exclude infection, and imaging studies such as CT scans or MRIs. The diagnosis is typically established through endoscopic procedures, namely colonoscopy, which permits direct visualization of the mucosal surfaces of the intestinal tract and tissue samples (biopsies) taken for further examination. For instance, as per a systematic review article published on 17 June 2024, reported that the incidence rate of Ulcerative Colitis and Crohn&rsquo;s Disease in the European region is approximately 24.3 and 12.7 per 100,000, respectively. The annual incidence rates for Ulcerative Colitis and Crohn&rsquo;s Disease in North America were reported at 19.2 and 20.2 per 100,000 individuals annually. The incidence of IBD in Asia ranges from 0.5 to 3.4 per 100,000 individuals, signifying the dynamic changing face of this emerging disease condition in the region. Incidence has risen over the past 10&ndash;15 years in Korea, Japan, China, Hong Kong, and India. The increase was more impressive in countries adopting a Western industrialized lifestyle.
Increase in the Prevalence of Inflammatory Bowel Disease
The increase in the prevalence of Ulcerative colitis and Crohn's disease is anticipated to fuel the growth of the inflammatory bowel disease market. Increasing inflammatory bowel disease is now emerging as a public health problem that is increasingly taking over industrialized nations. Several causes exist for the increase in this disease, with one significant cause being lifestyle changes: diets high on processed foods and low in fiber negatively impact health and gut health. In addition, the hygiene hypothesis provides an insight revealing that lower exposure to infections in the childhood period shows increased risk factors for autoimmune diseases, such as IBD. An urgent need to do further research into causes and treatments of IBD is a critical reason for the greater number of diagnosed cases. Public education campaigns are also needed towards communities about IBD for early detection and proper management of the disease. Considering that more people are living with the burden of IBD, managing this chronic illness needs a collective effort by providers, researchers, and policymakers to give better care and support to affected patients. For instance, in April 2024, Takeda Pharmaceutical Company Limited received approval from the U.S. Food and Drug Administration for ENTYVIO (vedolizumab) subcutaneous (SC) administration for the treatment in adults with moderately to severely active Crohn&rsquo;s disease (CD).
<h2>Advancements in the Treatment Options for Inflammatory Bowel Disease</h2>
Advancements in the treatment of inflammatory bowel disease include a wide approach to managing this chronic condition, such that patients are offered more effective and targeted therapies. Indeed, biologics, which target inflammatory pathways by specifically targeting cells, pathways, or molecules that contribute to inflammation, have revolutionized the management of this disease, from addressing underlying pathogenic mechanisms to the historical approach of symptom relief. Moreover, biologics like anti-TNF agents and integrin inhibitors have also proven useful in many patients' induction and maintenance of remission. New small molecules and JAK inhibitors are also emerging as additional alternatives in some cases. Personalized medicine has also advanced the ability of doctors to treat individual patients according to their individual genetic makeup and disease characteristics, thus offering a better chance for positive outcomes. Continued research and clinical trials are discovering additional new therapeutic targets, as well as new combination therapies, promising higher efficacy and safety. For instance, on 19 February 2024, Pfizer Inc. received approval from the European Commission (EC) granting marketing authorization for VELSIPITY (etrasimod) to treat patients 16 years of age and older with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or was intolerant to either conventional therapy or a biological agent. VELSIPITY is the first and only advanced oral ulcerative colitis treatment approved for use in patients 16 years of age.
<h2>Crohn&rsquo;s Disease Segment to Dominate the Inflammatory Bowel Disease Market</h2>
The Crohn's disease segment dominates the inflammatory bowel disease market due to the high prevalence and the specific need for treatment. Often, Crohn's disease affects any part of the gastrointestinal tract and generally causes more severe and varied symptoms than ulcerative colitis does, so its requirements are more complex, thus dictating a wide range of treatment options, including biologics, immunosuppressants, and emerging therapies tailored according to the needs of the individual patient. Other drivers for the growth of this segment include improved diagnosis techniques and increased awareness. Research and clinical studies in Crohn's disease continue to drive ongoing innovations and therapies that improve patient outcomes significantly, thus driving growth in the market. Also, with healthcare providers seeking more practical treatments for this chronic condition, the Crohn's disease market is poised to capture a greater share of the inflammatory bowel disease market. For instance, on 18 May 2023, AbbVie Inc. received approval from the U.S. Food and Drug Administration for RINVOQ (upadacitinib) to treat adults with moderate to severely active Crohn's disease.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<h2>North America Dominates Inflammatory Bowel Disease Market&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</h2>
North America dominates the Inflammatory Bowel Disease (IBD) market, primarily driven by a combination of high prevalence rates, advanced healthcare infrastructure, and significant investment in research and development. The incidences of ulcerative colitis in North America range from 2.2 to 19.2 cases per 100,000 person-years, and Crohn&rsquo;s disease incidences range from 3.1 to 20.2 cases per 200,000 person-years. In the United States the prevalence of adult ulcerative colitis was 238 per 100,000 population and 201 per 100,000 population with data from a large study based on insurance claims. Inflammatory bowel disease is more prevalent in North America and Europe than in Asia or Africa. The region has a well-established healthcare system that makes it easier to administer new, advanced therapies such as biologics and emerging medications specifically designed to meet the needs of each patient. Well-organized awareness programs and support groups help facilitate earlier diagnosis and optimal management of the disease. For instance, on August 12, 2024, Celltrion USA, Inc. (Celltrion USA) received approval from the Food and Drug Administration for biosimilar adalimumab-aaty. Adalimumab-aaty is approved for the treatment of patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease and Ulcerative colitis. The treatment for self-funded employer plans was available in the U.S. from Costco Specialty Pharmacy on October 1, 2023.
<a href="https://www.marketsandata.com/industry-reports/inflammatory-bowel-disease-market/sample-request">Download Free Sample Report</a>
Future Market Scenario (2024-2031F)
The future market scenario seems promising for the inflammatory bowel disease market, influenced by factors that increase demand and investment in this market. The inflammatory bowel disease market is full of promise with the continuous advancement in research, technology, and options available for treatment. Moving into the future, with an increased understanding of the mechanisms driving IBD, more targeted therapies are emerging, such as biologics and small molecules targeting some of the pathways responsible for inflammation. In addition, the increasing incidence of IBD in emerging markets and globally will increase the patient population, which requires effective management systems. Improved diagnosis and early detection methods will ensure timely interventions, which will be beneficial to the patients and improve their quality of life. Other factors that will drive innovation in the field are stronger investment in research and more collaboration between pharmaceutical companies and academic institutions. For instance, on 4 October 2023, Sanofi and Teva Pharmaceuticals announced a collaboration to co-develop and co-commercialize asset TEV&rsquo;574, currently in Phase 2b clinical trials for the treatment of Ulcerative Colitis and Crohn's Disease, the two types of inflammatory bowel disease.
Report Scope
&ldquo;Inflammatory Bowel Disease&nbsp;Market Assessment, Opportunities and Forecast, 2017-2031F&rdquo;,&nbsp;is a comprehensive report by Markets and Data, providing in-depth analysis and qualitative and quantitative assessment of the current state of global inflammatory bowel disease market, industry dynamics, and challenges. The report includes market size, segmental shares, growth trends, opportunities, and forecast between 2024 and 2031. Additionally, the report profiles the leading players in the industry, mentioning their respective market share, business models, competitive intelligence, etc.
<table>
<tbody>
<tr>
<td width="301">
Report Attribute
</td>
<td width="301">
Details
</td>
</tr>
<tr>
<td width="301">
Base Year of the Analysis
</td>
<td width="301">
2023
</td>
</tr>
<tr>
<td width="301">
Historical Period
</td>
<td width="301">
2017-2022
</td>
</tr>
<tr>
<td width="301">
Forecast Period
</td>
<td width="301">
2024-2031
</td>
</tr>
<tr>
<td width="301">
Projected Growth Rate
</td>
<td width="301">
CAGR of 5.15% between 2024 and 2031
</td>
</tr>
<tr>
<td width="301">
Revenue Forecast in 2031
</td>
<td width="301">
USD 32.98 billion
</td>
</tr>
<tr>
<td width="301">
Segments Covered
</td>
<td width="301">
Type, Drug Class, Route of Administration, Distribution
</td>
</tr>
<tr>
<td width="301">
Regions Covered
</td>
<td width="301">
North America, Europe, South America, Asia-Pacific, Middle East and Africa
</td>
</tr>
<tr>
<td width="301">
Key Companies Profile
</td>
<td width="301">
AbbVie Inc., Johnson &amp; Johnson Services, Inc., Pfizer Inc., Merck &amp; Co., Inc., Novartis AG., Amgen Inc., Takeda Pharmaceutical Company Limited., UCB S.A., CELLTRION INC., Bristol Myers Squibb.
</td>
</tr>
<tr>
<td width="301">
Customization Scope
</td>
<td width="301">
15% free report customization with purchase
</td>
</tr>
<tr>
<td width="301">
Pricing and Purchase Options
</td>
<td width="301">
Avail the customized purchase options to fulfill your precise research needs
</td>
</tr>
<tr>
<td width="301">
Delivery Format
</td>
<td width="301">
PDF and Excel through email (subject to the license purchased)
</td>
</tr>
</tbody>
</table>
In the report,&nbsp;global inflammatory bowel disease market&nbsp;has been segmented into the following categories:&nbsp;
<ul>
<li>By Type
<ul>
<li>Ulcerative Colitis</li>
<li>Crohn&rsquo;s Disease</li>
</ul>
</li>
<li>By Drug Class
<ul>
<li>Corticosteroids</li>
<li>TNF Inhibitors</li>
<li>Amino salicylates</li>
<li>IL Inhibitors</li>
<li>JAK Inhibitors</li>
<li>Anti-integrin</li>
<li>Others</li>
</ul>
</li>
<li>By Route of Administration
<ul>
<li>Oral</li>
<li>Injectable</li>
</ul>
</li>
<li>By Distribution
<ul>
<li>Hospitals Pharmacies</li>
<li>Retail Pharmacies</li>
<li>Online Pharmacies</li>
<li>Others</li>
</ul>
</li>
<li>By Region
<ul>
<li>North America</li>
<li>Europe</li>
<li>Asia-Pacific</li>
<li>South America</li>
<li>Middle East and Africa</li>
</ul>
</li>
</ul>
Key Players Landscape and Outlook
The inflammatory bowel disease market is highly dynamic, with players like AbbVie Inc., Pfizer Inc., and many more. Market activity reported in recent years includes business agreements, collaborations, and regulatory approvals of market players' products. The market also fosters several smaller players, which operate through collaborations with other players to cater to a larger market.
On 8 July 2024, Eli Lilly and Company agreed to acquire Morphic Holding, Inc. to advance a first-in-class oral integrin treatment for serious chronic diseases, such as ulcerative colitis. Under the agreement, Lilly will acquire all outstanding shares of Morphic for approximately USD 3.2 billion.&nbsp;
On 28 June 2023, Eli Lilly and Company announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for mirikizumab (OMVOH) to treat moderately to severely active ulcerative colitis of adult patients.&nbsp;
Key Players Operating in Global Inflammatory Bowel Disease Market are:
<ul>
<li>AbbVie Inc.</li>
<li>Johnson &amp; Johnson Services, Inc.</li>
<li>Pfizer Inc.</li>
<li>Merck &amp; Co., Inc.</li>
<li>Novartis AG.</li>
<li>Amgen Inc.</li>
<li>Takeda Pharmaceutical Company Limited.</li>
<li>UCB S.A.</li>
<li>CELLTRION INC.</li>
<li>Bristol Myers Squibb.</li>
</ul>
Markets and Data report answers the following questions:
<ul>
<li>What is the current and future market size of the product/service in question globally or specific to different countries?</li>
<li>How are the markets divided into different product/service segments and the market size and growth of each segment?</li>
<li>What is the market potential of different product segments and their investment case?</li>
<li>How are the markets predicted to develop in the future and what factors will drive or inhibit growth?</li>
<li>What is the business environment and regulatory landscape specific to the product/service?</li>
</ul>
If you can't find what you're searching for or have any custom requirements for global inflammatory bowel disease market, you may approach our team at&nbsp;<a href="mailto:info@marketsandata.com">info@marketsandata.com</a>.

Global Inflammatory Bowel Disease Market Assessment, Opportunities and Forecast, 2017-2031F

The inflammatory bowel disease market is expected to experience growth due to rising prevalence, advancements in treatment options, and increased awareness. Biologics and personalized medicine are transforming management treatment strategies.

FAQs

Industry Reports

Blogs

Case Studies

Industry News

Press Release

Infographics